Whitepaper: Global regulators’ FAQs on CMC in IND/BLA filing

Mammalian cell cultures used in the manufacturing of therapeutics must be tested to ensure lack of mycoplasmal contamination. Previously, the only test for mycoplasma accepted by regulatory agencies was a culture-based test such as the test detailed in USP <63>. Currently, regulatory agencies globally accept nucleic acid testing methods as an alternative to the 28-day test, following acceptable validation, submission and review. This whitepaper will help readers understand some of the regulatory inquiries related to rapid mycoplasma testing and validation, and provide insight into potential responses.

Download Document

    Please fill out the information below to request information on the products you selected. If you are already registered, or have requested a quote before, and this information will be filled out for you.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

  • Yes, I would like to be contacted by a Thermo Fisher Scientific Sales representative to discuss the MycoSEQ Mycoplasma Detection System *
    Yes, I agree for the Thermo Fisher Scientific group to contact me by email to inform me of events, products, services and promotions offered in connection with which they believe may be of interest to me *

  • By submitting my personal data to CompareNetworks, I acknowledge it will be shared with the Thermo Fisher Scientific group for processing in accordance with the Thermo Fisher Scientific Privacy Policy. I can withdraw my consent and unsubscribe at any time by emailing [email protected].